Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An IDH-mutant, and 1p/19q-codeleted oligodendroglioma that is characterized as grade 3 tumors associated with a more rapid growth. Grade 3 tumors appear to have abnormalities on chromosomes 9 or 10, along with unusual amounts of growth factors and proteins, which are thought to contribute to the more rapid growth of these gliomas.
Biomarker and diagnostic research for oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3 has been reported in the published literature.
No clinical trials have been registered for oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3.
26 publications have been identified in PubMed for oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3. Research spans Review / Meta-Analysis (27%), Basic Science / Preclinical (23%), and Clinical Trial Publication (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 7 | 27% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 6:21 PM UTC
Laboratory research |
6 |
23% |
Clinical study results | 5 | 19% |
Disease patterns and progression | 4 | 15% |
Testing and diagnosis research | 3 | 12% |
New treatment approaches | 1 | 4% |
Müther M (2026). [PMID: 40926130](https://pubmed.ncbi.nlm.nih.gov/40926130/). *European journal of nuclear medicine and molecular imaging*. [Diagnostic / Biomarker]
Brat DJ (2026). [PMID: 42152226](https://pubmed.ncbi.nlm.nih.gov/42152226/). *Neuro Oncol*. [Review / Meta-Analysis]
Hata N (2026). [PMID: 41890358](https://pubmed.ncbi.nlm.nih.gov/41890358/). *Neurooncol Adv*. [Clinical Trial Publication]
Karsonovich T (2026). [PMID: 32809503](https://pubmed.ncbi.nlm.nih.gov/32809503/). *Unknown Journal*. [Review / Meta-Analysis]
Ozono I (2026). [PMID: 41189118](https://pubmed.ncbi.nlm.nih.gov/41189118/). *Japanese journal of clinical oncology*. [Clinical Trial Publication]
Figarella-Branger D (2025). [PMID: 39432559](https://pubmed.ncbi.nlm.nih.gov/39432559/). *Neuro-oncology*. [Review / Meta-Analysis]
Zhou J (2025). [PMID: 40384650](https://pubmed.ncbi.nlm.nih.gov/40384650/). *Quantitative imaging in medicine and surgery*. [Basic Science / Preclinical]
Kacimi SEO (2025). [PMID: 39356975](https://pubmed.ncbi.nlm.nih.gov/39356975/). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. [Clinical Trial Publication]
Rudà R (2025). [PMID: 40479721](https://pubmed.ncbi.nlm.nih.gov/40479721/). *Expert opinion on pharmacotherapy*. [Basic Science / Preclinical]
Rincon-Torroella J (2025). [PMID: 39382617](https://pubmed.ncbi.nlm.nih.gov/39382617/). *Journal of neuro-oncology*. [Clinical Trial Publication]